Telix Pharmaceuticals completes cyclotron installation in Belgium, set to produce vital medical isotopes in early 2025.
Telix Pharmaceuticals has finished installing two cyclotrons at its new manufacturing facility in Belgium, set to produce key medical isotopes like gallium-68 and zirconium-89. One cyclotron will support clinical and commercial needs, while the other will focus on research. The facility, expected to begin operations in early 2025, will serve the Europe, Middle East, and Africa regions, enhancing access to radiopharmaceuticals.
3 months ago
6 Articles